Skip to main content

4 Result(s)

within Julie A. Hixon Remove this filter

and

  1. No Access

    Article

    New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models

    Pediatric T cell acute lymphoblastic leukemia (T-ALL) cells frequently contain mutations in the interleukin-7 (IL-7) receptor pathway or respond to IL-7 itself. To target the IL-7 receptor on T-ALL cells, muri...

    Julie A. Hixon, Caroline Andrews, Lila Kashi, Casey L. Kohnhorst… in Leukemia (2020)

  2. Article

    Open Access

    A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia

    T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer for which treatment options often result in incomplete therapeutic efficacy and long-term side-effects. Interleukin 7 (IL-7) an...

    Padma Akkapeddi, Rita Fragoso, Julie A. Hixon, Ana Sofia Ramalho… in Leukemia (2019)

    Download PDF (2907 KB) View Article

  3. No Access

    Article

    Mutant IL-7Rα and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia

    Sarah D. Cramer, Julie A. Hixon, Caroline Andrews, Ross J. Porter… in Leukemia (2018)

  4. No Access

    Article

    Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

    João Barata and colleagues identify somatic gain-of-function IL7R mutations in childhood T-cell acute lymphoblastic leukemia. The mutations result in constitutive receptor activation, implicating the IL-7R pathwa...

    Priscila P Zenatti, Daniel Ribeiro, Wenqing Li, Linda Zuurbier… in Nature Genetics (2011)